Lv1
6 积分 2022-05-16 加入
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review
2个月前
已完结
Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants
2个月前
已关闭
Breast cancer surveillance following ovarian cancer in BRCA mutation carriers
2个月前
已完结
中国女性乳腺癌群体筛查与机会性筛查的比较研究
2个月前
已关闭
中国适龄女性乳腺癌筛查服务的可及性——筛查率及其构成分析
2个月前
已完结
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
2个月前
已完结
Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype
3个月前
已完结
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
3个月前
已完结
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
3个月前
已完结
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
3个月前
已完结
皖公网安备34019202002308
